← Surfer · Sage hub

Sage — Cardiology: Mitochondrial Energy → Cardiovascular Phenotype

Surfer Coach Sage

1. Framing — compensatory cascade → cardiovascular phenotype

Chronic diseases of modernity share a recurring upstream pattern in the EnSurf map: persistent cellular bioenergetic insufficiency rooted in mitochondrial dysfunction. Aging reads as progressive loss of ATP-generating capacity; cancer as fermentative escape when oxidative headroom collapses; fuel mismatch as wrong substrates degrading the membrane theater of oxidation; organ dysfunction as named syndromes that are higher-order compensations. Cardiovascular phenotypes belong in the same geometry — vessel wall, myocardium, autonomic control under orthostasis, and (as proposed bridge below) excitability/conduction that depends on ion-pump ATP.

The standing rule (Compensatory-cascade) is simple: when ATP load exceeds ATP-generating capacity, the system reverts to more primitive (lower) nests of energy production to keep generating enough ATP to maintain persistence. Acute emergency-mode can be adaptive and reversible. Chronic emergency-mode lock-in is what we call disease. Restore capacity in time and much of the cascade can wind down; fail to restore and selection hardens emergency-adapted phenotypes. Cardiology’s named syndromes — plaque, orthostatic tachycardia, hypertrophy/fibrosis, pressure elevation, rhythm instability — are readable first as clusters of that chronic mode under different tissue clocks and loads, not as freestanding villains inventing disease beside the engine.

Stay monist: Shore / Surf Judge language names orientation inside one field — not a second “mind stuff” beside mitochondria, and not a moral story in which lipids, rate, or pressure are villains independent of cellular fuel handling (Dashboard-discipline: map ≠ terrain; instruments, not a second ontology). The bioenergetics here follows Nick Lane’s work; cascade framing, Surfer/Energy Phase, and EN overlay are EnSurf’s own extensions, not Lane’s claims.

2. Atherosclerosis — mitochondrial-metabolic hypothesis addendum)

Hypothesis language throughout — not a protocol, not a statin-stop order, not a claim that apoB biology is false.

The standard ApoB retention model (respected, incomplete)

The dominant clinical paradigm holds that atherosclerosis is fundamentally a disorder of cholesterol retention in the arterial wall, delivered by apoB-containing lipoproteins (LDL, VLDL remnants, Lp(a)). ApoB particles act as delivery trucks; once trapped by subendothelial proteoglycans, cargo oxidizes, triggers macrophage foam-cell formation, and drives inflammation and plaque. ApoB count is the superior biomarker because each particle carries one apoB molecule. Lifelong low apoB virtually eliminates disease; elevated levels — amplified by insulin resistance raising triglycerides and particle number — explain risk. Lowering apoB reduces events in RCTs, Mendelian randomization, and familial hypercholesterolemia (FH). Lifestyle is foundational; pharmacotherapy achieves targets when needed.

This framework’s predictive power and clinical utility are real. It advanced risk stratification and saved lives. The metabolic hypothesis does not reject apoB measurement or lowering. It contextualizes particles within the bioenergetic state of vascular cells — and asks why retention, oxidation, and residual events occur where they do.

Where the apoB-centric model falls short

Explanatory gaps show up in discordant phenotypes and residual risk:

  • Insulin resistance as “other factor.” The standard model often treats IR as a parallel accelerator rather than an upstream driver mechanistically linked to endothelial dysfunction, inflammation, hypertension, and dyslipidemia — leaving the metabolic syndrome cluster without a unifying cellular account.
  • Discordance. Some with lifelong high apoB (e.g., lean mass hyper-responders on ketogenic diets) show minimal plaque on CAC or CTA, while others with modest elevations progress aggressively. Invoking “additional factors” without mechanism weakens prediction. If particles were sufficient once retained, progression should be more consistent across high-apoB states.
  • Residual risk. Often >70% of events persist despite aggressive apoB lowering. Attributing the gap solely to non-adherence or non-LDL factors feels incomplete without an upstream account of why dashboard optimization does not fully restore vascular health.
  • FH as extracellular overload alone. Framing FH as simple “excess delivery overwhelming clearance” overlooks intracellular dynamics. LDL-receptor defects impair cellular cholesterol uptake, creating relative sterol starvation that can divert mevalonate flux from CoQ10 toward compensatory sterol synthesis — a systemic mitochondrial energy deficit atop the lipid abnormality, better explaining accelerated atherosclerosis and statin side-effect overlap (myalgia, fatigue) than extracellular overload alone.
  • Metabolic-first outcomes. Patients who first optimize metabolism through diet, circadian alignment, and resistance training often achieve substantial, sustainable improvements with less polypharmacy. The apoB model neither strongly predicts nor easily explains these outcomes.

The mitochondrial-metabolic hypothesis

The root, in this map, is one layer upstream: mitochondrial dysfunction — impaired oxidative phosphorylation, excessive mtROS, and failed quality control (mitophagy, fission/fusion) — within endothelial cells, macrophages, and vascular smooth-muscle cells.

When endothelial mitochondria underperform, nitric oxide falls, adhesion molecules rise, and barrier integrity weakens, increasing lipoprotein permeability and retention. Dysfunctional macrophage mitochondria impair lipid handling and release mtDAMPs that activate NLRP3 inflammasome, fueling chronic plaque inflammation. Vascular smooth-muscle mitochondrial impairment promotes apoptosis and matrix degradation, thinning the fibrous cap.

Mitochondrial dysfunction appears early in vascular pathology; mtDNA damage, elevated mtROS, and bioenergetic failure correlate with plaque burden and instability. Hyperglycemia, aging, and hyperlipidemia exacerbate it, but impairment itself can initiate endothelial dysfunction — the accepted atherogenesis starting point.

The metabolic syndrome cluster follows naturally. Impaired oxidative phosphorylation drives glycolytic compensation (Warburg-like shift) and NF-κB activation. Hyperinsulinemia compensates by forcing glucose uptake but also drives hepatic VLDL oversecretion (elevated apoB) and blocks adipose lipolysis (central obesity). Hypertension emerges partly as perfusion compensation through energy-starved vessels. Obesity functions as “dashboard fat storage” when mitochondrial lipolysis fails.

Early, on this hypothesis, that shift is Crabtree-like and reversible: endothelial, smooth-muscle, and macrophage mitochondria remain competent and the cell can return to baseline. When the load persists, it may lock into a Warburg-like state. The plaque is the histological record of chronic compensatory lipid handling in cells lacking sufficient ATP to perform housekeeping cleanly.

Vicious cycles exist — oxidized LDL further damages mitochondria — but these amplify, not originate. Directional integrity holds: bioenergetic deficit precedes and drives lipoprotein and inflammatory changes. ApoB particles become more retained and oxidized because arterial-wall cells are energetically compromised and cannot handle lipids properly. Chronic mitochondrial impairment generates mtROS, pseudo-hypoxia, NF-κB/NLRP3 activation, endothelial vulnerability, hyperinsulinemia, and impaired lipolysis — a single upstream defect that accounts for the metabolic syndrome cluster, LMHR outliers, deeper FH pathophysiology, and apoB drops from strength training in obese diabetics.

Phenotypes the upstream lens reframes

  • Lean mass hyper-responders: high apoB with minimal plaque because vascular mitochondria remain efficient — “healthy engine, high dashboard.”
  • Obese diabetics after strength training: apoB drops via improved mitochondrial biogenesis and insulin sensitivity, without primary lipid drugs as the sole lever.
  • Familial hypercholesterolemia: receptor defect creates intracellular sterol/isoprenoid imbalance that impairs mitochondrial function systemically, accelerating vascular energy failure beyond particle retention alone. Germline — every cell, not only the liver. Extracellular lipid abundance with impaired regulated import (“water, water everywhere”) can still drive costly de novo cholesterol synthesis via mevalonate, diverting from the CoQ10 branch that supports electron transport.
  • Statin effects: benefits include apoB lowering plus pleiotropic anti-inflammatory and mitochondrial stabilization; limitations (myalgia from CoQ10 depletion, residual events) are predictable when therapy targets dashboard more than engine.

Foam cells, in this hypothesis, are metabolically desperate macrophages — not simple lipid dumps. Oxidized LDL and related cargo present as improper fuel: lipids that intensify mitochondrial lipid peroxidation, electron-transport leakage, and mtROS when internalized into already stressed cells. Pseudo-hypoxic, Warburg-like shifts recapitulate energy-failure signaling familiar from other Surf Judge pages. Plaque is then readable as a repair and walling-off record — fibrosis, calcification, necrotic core — left on when level 0–1 persistence in the wall cannot resolve the crisis.

Fuel essays add a membrane mechanism consistent with the same map. Industrial seed-oil–dominant PUFA loads incorporate into cellular and mitochondrial membranes, peroxidize under ROS, generate reactive aldehydes (including 4-HNE), adduct electron-transport proteins, and contribute to endothelial and vascular injury — often interacting with metabolic endotoxemia and mitochondrial dysfunction in vascular cells themselves. That is substrate architecture degrading the theater in which fat oxidation should occur cleanly — not a claim that every gram of linoleate is destiny, and not a protocol. Inflammation framing converges: atherosclerosis as downstream of endothelial and vascular energy crisis, with inflammatory programs as compensations that fail to stand down.

Parsimony, comprehensiveness, falsifiability

Occam’s razor favors fewer entities with equal or greater explanatory power. The apoB model requires multiple independent inputs (genetics + diet + insulin resistance + aging) converging on particle elevation and retention. The mitochondrial-metabolic hypothesis reduces these toward one primary mechanism — mitochondrial fuel-utilization failure — that generates hyperinsulinemia, hepatic lipid export, endothelial permeability, inflammation, compensatory hypertension, obesity, and amplified lipoprotein toxicity. ApoB retention becomes a modulated consequence, explaining why particle number alone predicts poorly in insulin-sensitive states.

Comprehensiveness is broader: metabolic syndrome as coherent downstream of mitochondrial failure; LMHR and carnivore outliers as high-dashboard/healthy-engine states; exercise-induced apoB drops as engine repair; modern dietary harms (chronic insulinogenic overload, seed-oil mitochondrial stress) as evolutionary mismatch; statin pleiotropy and boundaries; parallels with cancer Warburg shifts as primitive compensation for energy deficit.

The model is falsifiable in principle. Prospective pairing of mitochondrial biomarkers (mtDNA heteroplasmy, OXPHOS efficiency) with apoB in LMHR/FH cohorts, or trials of mitochondrial support plus low-dose statin versus high-intensity statin alone, would distinguish frameworks. Mitochondrial cardiovascular literature is mechanistically rich though historically lighter on large outcomes trials than apoB research. The frameworks are complementary — apoB remains a valuable proxy — but the upstream lens better guides prioritization and explains why metabolic optimization often normalizes the dashboard sustainably with wider benefits. Working hypothesis, not a randomized-trial verdict that mitochondrial-first strategies outperform guideline apoB lowering as monotherapy.

Therapeutic implication language (engine first; pharmacology adjunct)

If mitochondrial bioenergetic failure is root, therapy begins with engine restoration. In the EnSurf system this means three domains — hypothesis, not orders:

  • Fuel: nutrient-dense animal proteins and fats for bioavailable nutrients; fermented metabolizable carbohydrates (MACs) for microbiome support; strategic fasting or time-restricted eating where appropriate; avoid chronic hyperinsulinemic and seed-oil–dominant patterns that impair mitochondrial membrane handling. Targeted cofactors appear in the primary essay as researched supports in context (including CoQ10, NAD+-pathway supports, and related mitochondrial tools named elsewhere on site) — still hypothesis under medical supervision, not a retail dosing protocol.
  • Circadian: morning sunlight, dim evenings, consistent sleep — support mitochondrial quality control and reduce chronic pseudo-hypoxic signaling.
  • Strength: dynamic resistance training drives mitochondrial biogenesis and insulin sensitivity. Grip strength and functional capacity serve as practical surrogates of systemic bioenergetic health.

Lipid-lowering drugs retain a role when genetic or advanced disease makes lifestyle optimization insufficient — adjunct rather than sole primary when the map is engine-first. Patients guided through mitochondrial-first protocols frequently achieve meaningful apoB reductions alongside gains in energy, body composition, inflammation, and metabolic flexibility — often with lower medication burden. This ordering is pro-root-cause, not anti-pharmacology: when the engine runs better, the dashboard improves as consequence. This page does not invent peptide, HRT, or GLP-1 regimens, does not authorize stopping cardiology meds from a webpage, and does not promise plaque reversal.

The Good Doctor puts the same inversion in clinical language: the foam cell is not an independent villain; it is a macrophage that could not keep house on the fuel and signals it was given. An LDL number chased in a person whose mitochondria oxidize fat cleanly is a dashboard reading that can become wrong when mistaken for the terrain. Conventional practice is not foolish for treating visible risk — pressure that will rupture, thrombus that will occlude, apoB high enough that specialty consensus favors lowering. The ontological error is taking the cluster as the disease and suppression of the cluster as the cure while the mismatch that made the cluster necessary continues.

Addendum — Lipoprotein(a) as amplifier of cellular energy failure

A particularly instructive case within the metabolic framework is Lipoprotein(a), or Lp(a). This ApoB-100–containing particle carries a unique, genetically polymorphic apolipoprotein(a) covalently bound to its surface. The apo(a) moiety confers prothrombotic activity through structural homology to plasminogen and inhibition of fibrinolysis, and serves as a principal carrier of oxidized phospholipids (OxPL) in human plasma.

In the conventional lipid-storage model, Lp(a) is viewed primarily as an additional atherogenic lipoprotein whose retention, oxidation, and scavenger-receptor uptake promote foam-cell formation and plaque progression. The metabolic perspective reframes pathogenicity around the quality of the cargo and the cellular bioenergetic state it encounters. Because Lp(a) constitutively bears OxPL on apo(a), it functions as a pre-damaged, “improper fuel” particle. When retained in the subendothelial space or internalized, these oxidized lipids exacerbate mitochondrial lipid peroxidation, ETC leakage, and mtROS — intensifying the bioenergetic crisis that arises from impaired lipid trafficking or CoQ10 depletion in the mevalonate pathway.

Lp(a) further accelerates downstream consequences of mitochondrial stress. Its OxPL content upregulates endothelial PFKFB3, driving a glycolytic shift that fosters a pro-adhesive, pro-inflammatory phenotype with increased ICAM-1 expression and monocyte recruitment — metabolic reprogramming that recapitulates pseudo-hypoxic, HIF-1α–linked states classically triggered by energy failure. Independent of ApoB levels, higher Lp(a) also correlates with elevated vascular superoxide production and eNOS uncoupling secondary to tetrahydrobiopterin depletion — redox dysregulation rooted in or amplifying mitochondrial ROS.

In LDL-receptor dysfunction (FH and related states), Lp(a) clearance is likewise impaired, elevating circulating concentrations and contributing to the same paradox of extracellular lipid abundance with deficient regulated import for mitochondrial oxidation. The prothrombotic properties of apo(a) then potentiate maladaptive repair and thrombus growth precisely where endothelial and platelet mitochondria are already compromised.

Importantly, Lp(a)-attributable risk is modulated by the host metabolic milieu. Just as LMHR phenotypes can sustain extreme LDL/ApoB elevations with limited plaque progression when oxidative capacity remains robust, individuals with high Lp(a) but preserved cellular fuel-handling resilience may experience slower disease progression. Particle number and damaged-lipid cargo matter; so does tissue capacity to process that cargo without irreversible injury.

Thus Lp(a) does not demand a separate causal ontology. It exemplifies how certain ApoB particles, distinguished by oxidized phospholipid burden and direct effects on cellular metabolism, accelerate the transition from mitochondrial energy failure to endothelial dysfunction, inflammatory recruitment, foam-cell persistence, and thrombosis. Atherosclerosis remains, at root in this map, a disease of cellular bioenergetic insufficiency; Lp(a) is one of its efficient accelerants when that insufficiency is already present. Emerging Lp(a)-specific lowering can reduce OxPL-laden cargo influx where specialty care judges it indicated; mitochondrial support and board work address handling capacity — complementarity, not competition.

2b. Nitric Oxide — energy flux manager

Hypothesis language only — not a nitrate/PDE5 protocol, not a blood-pressure drug holiday, not an erectile self-treatment guide. Do not start, stop, or combine nitrates, PDE5 inhibitors, or other vasoactive drugs from this page. Education only; no Rx advice.

Nitric oxide is conventionally taught as a vasodilator. That description is true and incomplete. NO is better understood as an energy-flux manager: a short-lived gas that simultaneously adjusts delivery of oxygen and substrate to working mitochondria, rations consumption of oxygen at cytochrome c oxidase so proximal organelles do not steal the entire gradient, and protects the conduit so that future flux is not obstructed by adhesion, thrombosis, and smooth-muscle overgrowth. When NO bioavailability is adequate and coupled, high energy flux is possible without proportional damage. When it is lost, the cell experiences a delivery-and-matching failure that the mitochondrial-metabolic hypotheses of aging and cancer already identify as upstream: chronic mismatch between ATP supply and maintenance demand.

Full essay: Sage — The Metabolic Hypothesis of Nitric Oxide.

Glaucoma: Three Compartments, One Matching Failure

Glaucoma has its own page: Sage — Glaucoma. That page covers the three compartments and what nitric oxide does in glaucoma.

PDE5 Inhibitors: Amplifier, Not Source

The vascular pharmacology of the class: Sage — Nitric Oxide.

The nitric oxide profile described above has two ocular chapters that must not be collapsed into one.

Cyanopsia---the blue color shift---is PDE6. Photoreceptor PDE6 hydrolyzes cGMP after a photon hits the opsin. That drop closes cation channels and starts the visual signal. Sildenafil is only about ten-fold selective for PDE5 over PDE6; tadalafil is far more selective. Partial PDE6 block leaves cGMP a little high after a flash, slows phototransduction, and impairs blue--green discrimination. Patients report a blue tinge, extra brightness, photophobia. It tracks plasma peak and clears in hours. It is not optic-nerve ischemia, and it is not known to predict NAION.

NAION is a perfusion-compartment event in a crowded disc. The optic nerve head sits in a tight scleral canal, supplied by short posterior ciliary arteries. Most patients who infarct that tissue already have a small cup-to-disc ratio---"disc at risk." A transient drop in perfusion pressure (mean arterial pressure minus intraocular pressure) below what that anatomy can tolerate produces axoplasmic stasis, swelling, and further compression. Many ordinary NAION cases are noticed on waking, and nocturnal hypotension has been proposed as a final insult.

A PDE5 inhibitor can be the last increment: mild systemic vasodilation, a nocturnal pressure dip after an evening dose, perhaps a small transient IOP rise. The drug does not clog the nerve. It lowers the pressure head in a nerve that had almost no anatomic reserve. Labels advise caution in anyone who has already had NAION, because recurrence risk is higher, and tell anyone with sudden vision loss to stop the drug and seek care. Absolute risk is low. Relative risk in selected observational analyses is on the order of twofold on a background of about 1 case per 10,000 person-years in people over 50. Causality is plausible, not a large population effect.

Keep the chapters separate. Blue vision is homology between two cGMP phosphodiesterases. NAION is a rare ischemic event in a structurally vulnerable nerve plus a blood-pressure dip. Neither is an argument for treating every optimized adult with daily tadalafil. Both are arguments for knowing the anatomy you are asking a drug to visit. The same anatomy---crowded disc, nocturnal dip, perfusion pressure as MAP minus IOP---is the acute version of the matching failure that, left chronic, is one corridor into glaucomatous nerve-head damage.

Vascular/cardiac depth lives on this page. Signaling-nest framing (NO beside adenosine / insulin as matching loops) also appears on Sage — Signals. Ocular shear–eNOS / glaucoma compartment language cross-links Sage — Eye.

3. Autonomic / POTS — orthostatic expression of constrained energy economy

POTS is conventionally framed as a primary disorder of autonomic regulation. Diagnostic criteria center on an excessive heart-rate rise upon standing (≥30 bpm adults / ≥40 bpm adolescents) without orthostatic hypotension, with chronic orthostatic intolerance that improves on recumbency. Subtypes (hypovolemic, neuropathic, hyperadrenergic, deconditioning-dominant) and algorithms emphasizing volume, compression, graded exercise, and symptom-targeted pharmacology are clinically useful — and incomplete. They describe the compensatory surface while leaving the energetic substrate largely unexamined.

The metabolic hypothesis reframes POTS as the orthostatic expression of constrained cellular energy economy. The tachycardia is not the disease; it is the system’s attempt to preserve cerebral perfusion and cardiac output when stroke volume falls and energy-dependent vascular and neural control falter under gravitational load. Mitochondrial inefficiency — often unmasked or induced by infection — reduces reserve in the tissues that matter most under orthostasis: vascular smooth muscle, autonomic nerves, cardiac myocytes, and the brain. Relative hypovolemia, impaired vasoconstriction, exaggerated sympathetic drive, and cardiac atrophy then emerge as interlocking downstream consequences rather than independent primary lesions.

Upon standing, hundreds of milliliters of blood pool in the lower body and splanchnic bed. Venous return declines, stroke volume drops, and baroreceptor unloading triggers compensatory tachycardia and vasoconstriction. In a metabolically robust individual the response is modest and effective. In the POTS patient the same gravitational stress elicits an exaggerated rate response because the capacity to maintain stroke volume and peripheral resistance has been compromised — energetically. High-demand tissues cannot maintain membrane potential, calcium handling, or contractile tone when oxidative phosphorylation is impaired. Cerebral neurons are exquisitely sensitive to modest energy shortfalls — brain fog and near-syncope follow.

Evidence cluster (hypothesis-supporting, not a protocol): fibroblast findings linking choline/betaine handling, membrane phospholipid ratios, oxygen consumption, membrane potential, and ROS; primary mitochondrial cytopathies producing orthostatic intolerance; overlap with ME/CFS energetics; post-viral (including long COVID) mitochondrial disruption — Complex I vulnerability, ROS cycles, NAD⁺ drain, fragile mitophagy, altered inner-membrane phospholipids. Subtypes then read as overlapping expressions of one energetic constraint: relative hypovolemia because volume regulation costs energy; neuropathic features as small-fiber/ganglia energy failure; hyperadrenergic drive as appropriate sympathetic response to inadequate output or cellular supply; deconditioning as both consequence and amplifier. Autoimmunity and unresolved post-viral immune activity fit as energetically expensive compensations when ATP capacity is already short of allostatic load.

Therapeutic logic in the Sage essay follows hierarchy without converting this Sage into orders: expand plasma volume and reduce pooling; progressive initially-recumbent reconditioning; substrate selection that favors metabolic flexibility and lowers peroxidation load; circadian alignment as non-negotiable autonomic stabilizer; wearable HRV/resting HR and grip as recovery dashboards; pharmacologic agents as temporary scaffolding while capacity rebuilds. Targeted mitochondrial cofactors appear in the essays as rate-limiting supports applied to documented deficits — still hypothesis language under medical supervision, not a retail dosing protocol. This page does not invent peptide, HRT, or GLP-1 regimens.

POTS is heterogeneous. The hypothesis does not require uniformity; it requires that cellular energy economy is a rate-limiting node in the majority and that addressing it can produce meaningful gains. In cascade vocabulary: orthostatic tachycardia is acute-looking compensation that becomes a chronic emergency phenotype when reserve never returns.

4. Organ dysfunction — multi-organ cardiac angle

From The Metabolic Hypothesis of Organ Dysfunction: organs are integrated tissue assemblies where specialized cells perform high-work functions supported by vascular, matrix, and local signaling networks. When level 0–1 ATP / redox homeostasis fails in key cell populations — fuel inefficiency (including peroxidized cardiolipin, proposed here to come from seed-oil PUFAs), hyperglycemia, cofactor gaps, circadian misalignment (which in mice disrupts PGC-1α-linked rhythms), ROS, mtDNA damage, impaired mitophagy — higher-level responses may activate: vascular remodeling, matrix reorganization, altered fluid dynamics, local immune clearance, functional adaptation or sacrifice of vulnerable cell types. In this model, acute activation can be adaptive; chronic persistence would reflect failed resolution.

The heart is named explicitly as a parallel organ of force equal to the ocular archetype. Cardiomyocytes possess a very high mitochondrial volume density to support continuous contractile work. Chronic level 0–1 insufficiency — from hypertension-induced pressure overload, ischemic episodes, diabetic glucolipotoxicity, or dietary insults that impair mitochondrial handling — may trigger compensatory hypertrophy to normalize wall stress despite inefficient sarcomere force generation; extracellular matrix remodeling and fibrosis may represent repair attempts that eventually stiffen the ventricle (HFpEF patterns) or dilate it (HFrEF patterns). Benefits of agents such as SGLT2 inhibitors in heart failure are read, in Organ Dysfunction framing, as possibly including favorable shifts in myocardial fuel utilization and reduced glucotoxicity on mitochondria — consistent with upstream support — without converting this essay into a prescribing guide.

Kidney and brain parallels matter for cardiology multimorbidity: proximal tubular / podocyte energy failure contributing to impaired reabsorption, proteinuria, scarring compensations; neuronal bioenergetic decline → protein mishandling, synaptic loss, gliosis, vascular cognitive impairment. Inflammaging and microglial activation as chronic clearance attempts mirror vessel-wall inflammatory persistence. Atherosclerosis and myocardial energy failure are therefore not separate ontologies. Vessel-wall bioenergetic collapse and myocyte bioenergetic collapse are tissue expressions of the same mismatch geometry under different clocks and loads. The eye remains the clinical window; the heart is the continuous engine under the same rule. Specialty cardiology owns minutes, ischemia, arrhythmia salvage, and procedure clocks. This Sage owns question order: engine before dashboard theater.

Cardiomyopathy and heart failure in depth: Sage — Cardiomyopathy and Heart Failure.

5. Hypertension — scar of matching failure

Hypertension-as-scar is covered in Sage — Nitric Oxide. That essay supplies the EnSurf-compatible account: chronic hypertension is not successful ATP compensation via higher cuff pressure; it is cross-system scar — uncoupled eNOS, high standing resistance, wall remodeling, and renal pressure-natriuresis reset — after matching loops were left on as architecture. This does not invent a BP-drug holiday or a Surfer antihypertensive protocol. Specialty care still owns pressure emergencies and indicated pharmacotherapy.

Primary hypertension in depth: Sage — A Metabolic Hypothesis of Hypertension.

Earlier peripheral mentions remain true and subordinate: The Good Doctor lists essential hypertension among chronic clinic faces of compensations that did not stand down; Organ Dysfunction treats hypertension-induced pressure overload as one driver of myocardial level 0–1 insufficiency.

6. Cardiac electrophysiology

Electrophysiology and arrhythmia in depth: Sage — Electrophysiology and Arrhythmia.

Bridge logic:

  • Ion pumps are ATP machines. Resting membrane potential, Na⁺/K⁺-ATPase work, and sarcoplasmic reticulum calcium cycling are among the most expensive continuous costs in excitable tissue. When mitochondrial ATP supply and redox order falter, excitability and conduction become less stable — the same geometry POTS already states for membrane potential and calcium handling in myocytes, smooth muscle, and autonomic axons under orthostatic load.
  • Adenosine as energy-stress dashboard. The Adenosine Energy Stress Signal essay frames adenosine/AMP as the high-frequency signal of ATP breakdown — protective braking and demand reduction when supply is short. That is dashboard language for energy stress in excitable systems, not an antiarrhythmic protocol and not a claim that every clinical arrhythmia is “only adenosine.”
  • Chronic emergency-mode. On the compensatory cascade, acute lower-nest compensation can preserve persistence; chronic lock-in (glycolytic bias, ROS, membrane lipid injury from Fuel mismatch) is the hypothesized substrate in which ectopy, conduction delay, or autonomic rate extremes become more likely. Plaque ischemia and myocyte energy failure (Organ Dysfunction) remain classic structural routes into the same phenotype space.

What this section refuses: fabricated EP trial citations; invented ablation/drug algorithms; peptide or hormone “rhythm protocols”; any implication that Fuel/light/strength coaching replaces ICD, anticoagulation, or EP lab timing. Specialty electrophysiology owns those clocks. It asks the Good Doctor’s question in a new tissue: is ATP-generating capacity sufficient and flexible for the electrical work this heart is being asked to do?

7. Conventional alternatives / Surf Judge — Good Doctor

Conventional cardiology has produced remarkable saves: reperfusion, devices, antiplatelet and anticoagulant pathways, pressure and rate control, lipid-lowering where indicated, structured rehab, HF drug classes that improve outcomes. The metabolic map does not compete with those minutes. It relocates question order.

Map ≠ terrain. LDL/ApoB, Lp(a), blood pressure, heart-rate rise on stand, EF, calcium score, wearable HRV — these are indispensable dashboards. They are not the organism’s Level 0–1 field. Treating the dashboard as the disease while the mismatch continues is the Good Doctor’s named error mode. Treating the constraint (restore oxidative capacity and fuel-handling resilience; reduce chronic emergency demand) is complementarity, not ideology against stents.

Therapeutic implication language already in the Lp(a) addendum and Organ Dysfunction: emerging Lp(a)-specific lowering can reduce OxPL-laden cargo influx where specialty care judges it indicated; mitochondrial support and board work address handling capacity; SGLT2i benefits in HF are readable partly as fuel-utilization shifts. EnSurf pillar translation remains hypothesis, not cardiac rehab orders:

  • Fuel: nutrient-dense patterns supporting beta-oxidation and TCA flux; avoid chronic hyperinsulinemic and seed-oil–dominant patterns that impair mitochondrial membrane handling — same Fuel geometry as other Sage pages.
  • Circadian: morning outdoor light, consistent sleep, dim evenings — support mitochondrial quality-control and autonomic stability; chaotic nights are engine noise.
  • Strength: progressive resistance and cardiorespiratory capacity as biogenesis stimuli; grip and fitness as honest systemic dashboards; for POTS, the essay emphasizes progressive, initially recumbent loading.

None of this authorizes stopping cardiology meds from a webpage, delaying stents or thrombolysis, coaching through syncope as a fasting experiment.

  • Fuel — membrane peroxidation, substrate architecture, vascular injury pathway.
  • Nitric Oxide (this page §2b) — 2.0 flux manager / scar grammar; Education only; no Rx advice.
  • Signals — hormones/peptides as higher coordination; NO matching-loop nest beside adenosine/insulin (no invented Rx / PDE5 protocols).
  • Serotonin — sibling flux manager (oxygen/carbon allocation); no Coach invention.
  • Thyroid — non-thyroidal illness / conservation dashboard under energy constraint; shared cascade geometry.
  • Aging — progressive ATP-capacity loss as shared spine.
  • Immune / inflammation — inflammatory persistence as compensation that never stood down; athero convergence.
  • Diabetes · Obesity — glucolipotoxicity and diabesity field for vessel and myocardium.
  • Eye — organ-dysfunction archetype; heart named as equal-force parallel.
  • Philosophy of Medicine — disease as chronic compensatory mode; Good Doctor ethos.
  • Methylene Blue — electron-carrier hypothesis; appears in the POTS essay as one researched support under supervision — not a cardiology cure claim here.

9. Limits of the claim

  • Working hypothesis. Not a randomized-trial verdict that mitochondrial-first strategies outperform guideline ApoB lowering, HF guidelines, or autonomic specialty algorithms as monotherapy.
  • Does not deny ApoB biology, OxPL, thrombosis, ischemia, structural heart disease, or the clinical utility of lipid-lowering, antiplatelet, antihypertensive, rate/rhythm, revascularization, or device care when indicated.
  • FH, elevated Lp(a), established ASCVD, syncope, and acute coronary syndromes remain high-stakes; specialty care owns those clocks.
  • Not covered here: valve disease. Ocular NO detail lives on Eye Sage.

10. Conclusion

Cardiology, in the Metabolic Hypothesis map, is what chronic emergency-mode metabolism looks like when the mismatch is written into vessel wall, myocardium, autonomic orthostatic control — and, as a proposed bridge, into the ATP-expensive electrical work of excitability and conduction. Atherosclerosis is more fundamentally a disorder of cellular energy handling in the vascular wall than of apoB retention alone — apoB particles, oxidized cargo, and Lp(a) as amplifiers of an upstream mitochondrial-metabolic crisis. POTS is orthostatic compensation when mitochondria cannot fully underwrite upright posture. Heart failure patterns are organ-level hypertrophy/fibrosis records of myocyte energy failure. Hypertension is now mapped as NO-matching scar, not as successful pressure compensation. Electrophysiology is invited into the same question order. Lipids, rate, pressure, and wearable scores are dashboards; mitochondria and fuel architecture are engine. The Good Doctor begins with persistence: whether ATP-generating capacity is sufficient and flexible for demand. Coach and Surfer give shorter versions. Cardiology still owns the emergency.

Topics in this chapter

A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 31, 2026.

References

4. Organ dysfunction — multi-organ cardiac angle

  1. Barth E, Stämmler G, Speiser B, et al., 1992. Ultrastructural quantitation of mitochondria and myofilaments in cardiac muscle from 10 different animal species including man. Journal of Molecular and Cellular Cardiology 24(7):669-681. doi:10.1016/0022-2828(92)93381-s
  2. Neubauer S, 2007. The failing heart--an engine out of fuel. New England Journal of Medicine 356(11):1140-1151. doi:10.1056/NEJMra063052
  3. McMurray JJV, Solomon SD, Inzucchi SE, et al., 2019. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine 381(21):1995-2008. doi:10.1056/NEJMoa1911303
  4. Ferrannini E, Mark M, Mayoux E, 2016. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care 39(7):1108-1114. doi:10.2337/dc16-0330

See the notice at the top of this page. Working hypothesis, not medical advice.